23/11/16 Ben Ashby Document1 #715370 Antigenic evolution of SARS-CoV-2 in immunocompromised hosts. |
|
+Citations (1)
- CitationsAdd new citationList by: CiterankMapLink[1] Antigenic evolution of SARS-CoV-2 in immunocompromised hosts
Author: Cameron A Smith, Ben Ashby Publication date: 11 November 2022 Publication info: Evol Med Public Health. 2023; 11(1): 90–100, PMCID: PMC10061940, PMID: 37007166 Cited by: David Price 1:26 AM 13 December 2023 GMT Citerank: (4) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 704036Immunology859FDEF6, 704045Covid-19859FDEF6, 715368Ben AshbyBen is an Associate Professor in the Department of Mathematics at Simon Fraser University.10019D3ABAB URL: DOI: https://doi.org/10.1093/emph/eoac037
|
Excerpt / Summary [Evolution, Medicine, and Public Health, 11 November 2022]
Objectives/aims: Prolonged infections of immunocompromised individuals have been proposed as a crucial source of new variants of SARS-CoV-2 during the COVID-19 pandemic. In principle, sustained within-host antigenic evolution in immunocompromised hosts could allow novel immune escape variants to emerge more rapidly, but little is known about how and when immunocompromised hosts play a critical role in pathogen evolution.
Materials and methods: Here, we use a simple mathematical model to understand the effects of immunocompromised hosts on the emergence of immune escape variants in the presence and absence of epistasis.
Conclusions: We show that when the pathogen does not have to cross a fitness valley for immune escape to occur (no epistasis), immunocompromised individuals have no qualitative effect on antigenic evolution (although they may accelerate immune escape if within-host evolutionary dynamics are faster in immunocompromised individuals). But if a fitness valley exists between immune escape variants at the between-host level (epistasis), then persistent infections of immunocompromised individuals allow mutations to accumulate, therefore, facilitating rather than simply speeding up antigenic evolution. Our results suggest that better genomic surveillance of infected immunocompromised individuals and better global health equality, including improving access to vaccines and treatments for individuals who are immunocompromised (especially in lower- and middle-income countries), may be crucial to preventing the emergence of future immune escape variants of SARS-CoV-2. |